^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial

Published date:
09/28/2022
Excerpt:
The phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced non-small cell lung cancer (NSCLC)....Exploratory biomarker analyses showed the potential association of NOTCH1–4 mutations with improved tislelizumab efficacy for both OS and PFS...
DOI:
https://doi.org/10.1016/j.jtho.2022.09.217
Trial ID: